Total Funding
75
79
Total FundingSeries B raised
Growth Score
-1 pts
Heat Score
33 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10013
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
- Onur Boyman: Co-founder
- Christoph Huber: Chief Scientific OfficerPast Role: Roche, Head of Immunology & Clinical Pathology
About the Company
Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
